| Literature DB >> 29976406 |
Xiao-Bing Wang1, Jing Zheng1, Jun-Jie Li1, Hai-Ying Yu1, Qi-Yan Li1, Li-Hua Xu1, Ming-Jie Liu1, Rui-Qing Xian1, Yang-En Sun2, Bing-Jie Liu3.
Abstract
This paper presents an application of ultra high-performance liquid-chromatography-quadrupole-TOF high resolution mass spectrometry (UHPLC-Q-TOF HRMS) for simultaneous analysis of 23 illegal adulterated aphrodisiac type chemical ingredients in health foods and Chinese Traditional Patent Medicines (CTPMs). The mass spectrometer was operated in Information Dependent Acquisition (IDA) mode, which provides crucial information for the elemental composition analysis, structure elucidation and quantitative analysis simultaneously. Quantitative analysis was performed using the peak areas of the precursor ions in the XICs. The method validation included assessment of selectivity, sensitivity, calibration curve, accuracy, precision, recovery, matrix effect and stability. The results show good linear relationship with the concentrations of the analytes over wide concentration ranges (e.g., 0.05-10 μg/g for sildenafil) as all the fitting coefficients of determination r2 are >0.9984. The detection limits (LODs) were in the range of 0.002-0.1 μg/g. The recoveries were able to reach 82.5-103.6%, while the matrix effects ranged from 87.7 to 109.3%. The intra- and inter-day accuracies were in the range of 82.3-113.8%, while the intra- and inter-day precision ranged from 0.4 to 13.6%. Among 40 batches of health foods and 32 batches of CTPMs (including 28 capsules, 32 tablets, 10 liquid and 2 pills) samples, 28 batches of heath foods were positive. The detected chemical ingredients involved sildenafil, tadalafil, aildenafil and sulfoaildenafil. This method can be used for the screening, identification and quantification of illegal adulterated aphrodisiac chemical ingredients in health foods and CTPMs. Moreover, the LC-Q-TOF MS is very useful to structural elucidation of unknown compound.Entities:
Keywords: Aphrodisiac chemical ingredients; Illegal adulteration; Q-TOF MS; Qualitation; Quantitation
Mesh:
Substances:
Year: 2018 PMID: 29976406 PMCID: PMC9303026 DOI: 10.1016/j.jfda.2018.02.003
Source DB: PubMed Journal: J Food Drug Anal Impact factor: 6.157
Fig. 1Chemical structures of studied 23 analytes.
Fig. 2Extracted ion chromatograms of 23 analytes in (A) blank matrices and (B) matrices spiked with 0.1 μg/g 23 analytes standards.
Fig. 3MS2 fragment ions of 23 analytes.
Retention time, accurate mass, correlation coefficients, linear ranges, LODs and LLOQs of 23 analytes.
| Analyte | Retention time (min) | Protonated ion mass [M + H]+ | Mass error (ppm) | Correlation coefficient (r2) | Linear range (μg/g) | LOD (μg/g) | LLOQ (μg/g) | |
|---|---|---|---|---|---|---|---|---|
|
| ||||||||
| Theoretical | Experimental | |||||||
| Apomorphine | 1.72 | 268.1332 | 268.1331 | −0.4 | 0.9995 | 0.15–10 | 0.05 | 0.15 |
| Yohimbine | 3.42 | 355.2016 | 355.2013 | −0.8 | 0.9994 | 0.15–10 | 0.05 | 0.15 |
| Phentolamine | 4.78 | 282.1601 | 282.1603 | 0.7 | 0.9991 | 0.05–8 | 0.02 | 0.05 |
| Noracetildenafil | 5.65 | 453.2609 | 453.2608 | −0.2 | 0.9991 | 0.05–10 | 0.02 | 0.05 |
| Acetildenafil | 6.12 | 467.2765 | 467.2761 | −0.9 | 0.9986 | 0.05–10 | 0.02 | 0.05 |
| Vardenafil | 6.70 | 489.2279 | 489.2274 | −1.0 | 0.9998 | 0.05–10 | 0.02 | 0.05 |
| Hydroxyhomosildenafil | 7.00 | 505.2228 | 505.2227 | −0.2 | 1.0000 | 0.05–10 | 0.02 | 0.05 |
| Sildenafil | 7.22 | 475.2122 | 475.2118 | −0.8 | 1.0000 | 0.05–10 | 0.02 | 0.05 |
| Homosildenafil | 7.63 | 489.2279 | 489.2274 | −1.0 | 1.0000 | 0.05–10 | 0.02 | 0.05 |
| Aminotadalafil | 7.83 | 391.1401 | 391.1403 | 0.5 | 0.9996 | 0.25–10 | 0.10 | 0.25 |
| Aildenafil | 7.87 | 489.2278 | 489.2274 | −0.8 | 1.0000 | 0.05–10 | 0.02 | 0.05 |
| Avanafil | 7.89 | 484.1858 | 484.1855 | −0.6 | 0.9993 | 0.05–10 | 0.02 | 0.05 |
| Demethyltadalafil | 8.10 | 376.1298 | 376.1294 | −1.1 | 0.9996 | 0.25–10 | 0.10 | 0.25 |
| Udenafil | 8.52 | 517.2592 | 517.2587 | −1.0 | 0.9992 | 0.05–10 | 0.02 | 0.05 |
| Tadalafil | 9.41 | 390.1448 | 390.145 | 0.5 | 0.9996 | 0.15–10 | 0.05 | 0.15 |
| Dapoxetine | 10.84 | 306.1852 | 306.1849 | −1.0 | 0.9984 | 0.005–2.5 | 0.002 | 0.005 |
| Testosterone | 12.25 | 289.2162 | 289.2161 | −0.3 | 0.9997 | 0.15–10 | 0.05 | 0.15 |
| Sulfoaildenafil | 13.05 | 505.2050 | 505.2048 | −0.4 | 0.9994 | 0.05–10 | 0.02 | 0.05 |
| Methyltestosterone | 13.58 | 303.2319 | 303.2321 | 0.7 | 0.9991 | 0.15–10 | 0.05 | 0.15 |
| Propoxyphenyl-thiohydroxyhomosildenafil | 13.76 | 535.2156 | 535.2152 | −0.7 | 0.9995 | 0.15–10 | 0.05 | 0.15 |
| Pseudovardenafil | 14.48 | 460.2013 | 460.2009 | −0.9 | 0.9991 | 0.05–10 | 0.02 | 0.05 |
| Norneosildenafil | 15.14 | 460.2013 | 460.2007 | −1.3 | 0.9994 | 0.05–10 | 0.02 | 0.05 |
| Testosterone propionate | 16.28 | 345.2424 | 345.2423 | −0.3 | 0.9998 | 0.25–10 | 0.10 | 0.25 |
Accuracy, precision, recovery, matrix effect and stability for the determination of 23 analytes (n = 5).
| Analyte | QC concentration (μg/g) | Accuracy (%) | Precision (RSD, %) | Recovery (Mean ± SD, %) | Matrix effect (Mean ± SD, %) | Stability (Mean ± SD, %) | ||
|---|---|---|---|---|---|---|---|---|
|
|
| |||||||
| Intra-day | Inter-day | Intra-day | Inter-day | |||||
| Apomorphine | 0.2 | 107.5 | 94.6 | 5.3 | 3.5 | 82.5 ± 7.6 | 95.7 ± 8.8 | 86 ± 5.3 |
| 2.5 | 96.1 | 95.7 | 3.4 | 4.5 | 94.1 ± 2.4 | 99.5 ± 3.1 | 94.7 ± 3.9 | |
| 8 | 99.6 | 99.1 | 5.6 | 2.8 | 94.3 ± 6.9 | 97.1 ± 1.2 | 97.2 ± 6.9 | |
| Yohimbine | 0.2 | 109.0 | 91.3 | 1.7 | 1.5 | 88.6 ± 5.4 | 100.8 ± 7.3 | 87.9 ± 7.6 |
| 2.5 | 100.0 | 99.2 | 1.1 | 2.0 | 97.1 ± 1.2 | 103.2 ± 1.4 | 94.2 ± 2.1 | |
| 8 | 99.3 | 93.9 | 1.6 | 2.1 | 93.9 ± 3.3 | 102.6 ± 2.3 | 91.7 ± 2.8 | |
| Phentolamine | 0.3 | 113.0 | 96.1 | 2.1 | 1.2 | 97.6 ± 3.4 | 109 ± 5.8 | 91.9 ± 2.2 |
| 2.5 | 98.7 | 90.7 | 1.3 | 6.7 | 97.2 ± 0.8 | 98.6 ± 0.7 | 100.9 ± 2.2 | |
| 8 | 99.4 | 89.1 | 0.6 | 1.6 | 97.5 ± 1.9 | 97.9 ± 1.7 | 101.1 ± 1.8 | |
| Noracetildenafil | 0.06 | 91.4 | 84.2 | 2.3 | 2.9 | 94.2 ± 4.3 | 102.4 ± 1.9 | 92.1 ± 2.1 |
| 0.5 | 106.8 | 102.4 | 1.4 | 1.1 | 98.7 ± 1.2 | 96.6 ± 1.5 | 96.7 ± 1.6 | |
| 8 | 101.7 | 100.0 | 0.7 | 1.6 | 98.7 ± 1.3 | 105.9 ± 0.8 | 98.4 ± 2.4 | |
| Acetildenafil | 0.06 | 83.0 | 83.4 | 1.6 | 1.9 | 99.2 ± 2.4 | 95 ± 1.1 | 100.4 ± 1 |
| 0.5 | 110.8 | 106.8 | 1.5 | 1.2 | 98.4 ± 1.5 | 101.2 ± 1.4 | 96.4 ± 1.9 | |
| 8 | 100.8 | 99.0 | 1.8 | 1.5 | 100 ± 2.8 | 106.3 ± 2.0 | 98.2 ± 2.1 | |
| Vardenafil | 0.06 | 91.9 | 90.7 | 2.6 | 4.4 | 101.3 ± 3.4 | 93.6 ± 2.2 | 98.7 ± 4.2 |
| 0.5 | 96.9 | 92.1 | 1.2 | 2.5 | 97.7 ± 1.7 | 95.2 ± 1.2 | 95.1 ± 2.6 | |
| 8 | 95.6 | 98.7 | 1.4 | 5.0 | 98.4 ± 1.2 | 96.7 ± 1.3 | 103.3 ± 6.2 | |
| Hydroxyhomosildenafil | 0.06 | 105.0 | 102.4 | 2.7 | 2.5 | 100.3 ± 4.3 | 103.2 ± 2.6 | 97.6 ± 3.6 |
| 0.5 | 97.9 | 91.4 | 2.1 | 0.8 | 96.3 ± 3.1 | 99.4 ± 2.1 | 93.4 ± 1.8 | |
| 8 | 97.1 | 94.7 | 1.1 | 2.9 | 98.4 ± 0.7 | 97.1 ± 1.0 | 97.6 ± 3.7 | |
| Sildenafil | 0.06 | 92.4 | 87.5 | 7.8 | 4.2 | 96.6 ± 8.6 | 94.4 ± 5.7 | 91.7 ± 6.4 |
| 0.5 | 97.5 | 92.7 | 1.5 | 2.0 | 96.5 ± 0.8 | 97.1 ± 1.4 | 95.1 ± 2.7 | |
| 8 | 96.9 | 94.5 | 0.6 | 1.2 | 97.2 ± 1.2 | 96.7 ± 0.7 | 97.5 ± 1.7 | |
| Homosildenafil | 0.06 | 94.0 | 90.6 | 1.8 | 1.0 | 99.1 ± 3.8 | 95.9 ± 1.5 | 96.4 ± 1.8 |
| 0.5 | 98.2 | 94.4 | 1.3 | 1.4 | 97.6 ± 2.0 | 96.8 ± 1.3 | 96.1 ± 1.0 | |
| 8 | 97.0 | 96.5 | 1.2 | 3.5 | 98.1 ± 1.7 | 97.3 ± 1.1 | 99.5 ± 4.2 | |
| Aminotadalafil | 0.3 | 86.0 | 86.5 | 4.9 | 3.5 | 98 ± 12.4 | 109.3 ± 11 | 100.8 ± 7.5 |
| 2.5 | 95.1 | 92.3 | 2.2 | 1.7 | 96.7 ± 1.7 | 97.8 ± 4.6 | 97.1 ± 3.2 | |
| 8 | 96.0 | 92.8 | 3.2 | 1.1 | 94.3 ± 1.7 | 100.1 ± 0.8 | 96.8 ± 3.5 | |
| Aildenafil | 0.06 | 96.9 | 97.7 | 5.9 | 1.0 | 103.6 ± 5.8 | 99.5 ± 5.4 | 101.1 ± 5.8 |
| 0.5 | 99.7 | 96.5 | 1.1 | 0.7 | 98.2 ± 1.2 | 97 ± 1.0 | 96.9 ± 0.7 | |
| 8 | 96.3 | 95.3 | 0.6 | 3.2 | 97.8 ± 0.7 | 99.5 ± 0.7 | 99 ± 3.5 | |
| Avanafil | 0.06 | 82.8 | 80.0 | 1.5 | 1.4 | 96.6 ± 1.0 | 98.1 ± 1.1 | 96.6 ± 1.7 |
| 0.5 | 107.2 | 105.0 | 0.4 | 1.2 | 99.1 ± 0.7 | 92.4 ± 0.4 | 97.9 ± 1.4 | |
| 8 | 96.5 | 99.7 | 0.9 | 3.3 | 99.9 ± 1.2 | 102.8 ± 1.0 | 103.3 ± 3.9 | |
| Demethyltadalafil | 0.3 | 92.8 | 88.3 | 6.3 | 5.2 | 97.4 ± 4.7 | 104.4 ± 6.2 | 95.3 ± 3.6 |
| 2.5 | 96.0 | 91.8 | 1.9 | 1.5 | 95.9 ± 2.2 | 99.3 ± 2.3 | 95.7 ± 2.4 | |
| 8 | 96.6 | 93.0 | 1.5 | 1.8 | 96.3 ± 1.8 | 100.8 ± 0.8 | 96.3 ± 2.1 | |
| Udenafil | 0.06 | 95.1 | 91.8 | 1.2 | 1.2 | 95.3 ± 2.2 | 100.8 ± 1.2 | 96.6 ± 2.1 |
| 0.5 | 103.8 | 98.4 | 0.4 | 1.3 | 98 ± 1.3 | 99.2 ± 0.4 | 94.8 ± 1.4 | |
| 8 | 99.9 | 100 | 0.4 | 1.5 | 99.6 ± 1.0 | 103.1 ± 0.6 | 100.1 ± 1.4 | |
| Tadalafil | 0.18 | 102.4 | 113.8 | 1.9 | 12.1 | 87.3 ± 7.3 | 87.7 ± 8.4 | 111 ± 11.8 |
| 2.5 | 100.3 | 96.8 | 3.4 | 2.6 | 98.6 ± 1.4 | 94.3 ± 5.1 | 96.5 ± 4.7 | |
| 8 | 97.7 | 89.3 | 1.7 | 1.7 | 98.3 ± 1.0 | 99.1 ± 1.6 | 91.4 ± 3.0 | |
| Dapoxetine | 0.02 | 107.9 | 99.4 | 3.8 | 1.9 | 101 ± 7.4 | 100.6 ± 4.9 | 97.8 ± 8.4 |
| 0.25 | 108.2 | 112.7 | 1.4 | 1.8 | 98.2 ± 1.6 | 99.4 ± 1.1 | 101.6 ± 1.9 | |
| 2.5 | 93.5 | 95 | 1.7 | 3.6 | 97.4 ± 2.3 | 93.1 ± 1.9 | 106.4 ± 1.9 | |
| Testosterone | 0.2 | 103 | 91.8 | 6.4 | 7.8 | 94.4 ± 11.3 | 104.1 ± 6.3 | 87 ± 16.4 |
| 2.5 | 100.9 | 104.6 | 3.3 | 1.6 | 100.6 ± 2.5 | 104.3 ± 5.5 | 96.5 ± 7 | |
| 8 | 101.7 | 96.1 | 4.1 | 1.3 | 94.4 ± 4.1 | 105.6 ± 4.5 | 89.3 ± 3.7 | |
| Sulfoaildenafil | 0.06 | 96.1 | 94.4 | 6.6 | 7.6 | 101.3 ± 12.7 | 104.8 ± 4.4 | 98.6 ± 11.0 |
| 0.5 | 105.2 | 82.3 | 4.6 | 12.2 | 86.7 ± 4.4 | 96.2 ± 4.2 | 80.3 ± 6.0 | |
| 8 | 93.9 | 89.3 | 1.5 | 2.5 | 96.8 ± 1.3 | 96.7 ± 1.6 | 95.1 ± 3.5 | |
| Methyltestosterone | 0.2 | 101.6 | 95.9 | 6.4 | 5.3 | 99.4 ± 7.6 | 101.3 ± 2.2 | 96 ± 11.5 |
| 2.5 | 101.3 | 106.1 | 1.7 | 1.6 | 99.9 ± 3.5 | 100 ± 3.8 | 100 ± 3.8 | |
| 8 | 98.9 | 97.9 | 2.6 | 3.4 | 99.6 ± 2.5 | 101.2 ± 2.3 | 98.4 ± 3 | |
| Propoxyphenyl-thiohydroxyhomosildenafil | 0.2 | 105.4 | 91.6 | 8.2 | 13.6 | 97.3 ± 8.2 | 100.4 ± 5 | 87.8 ± 17.6 |
| 2.5 | 95.3 | 91.5 | 9 | 6.6 | 92.3 ± 9.4 | 97.1 ± 8.3 | 96.7 ± 11.1 | |
| 8 | 99 | 91.1 | 1.2 | 1.9 | 95.6 ± 2.9 | 101 ± 1.2 | 92.1 ± 2.5 | |
| Pseudovardenafil | 0.06 | 99.5 | 89.7 | 6.4 | 5.2 | 95.8 ± 5.2 | 108.9 ± 5.7 | 90.3 ± 5.8 |
| 0.5 | 102.4 | 97.3 | 2.2 | 2.7 | 97.9 ± 2.1 | 93.9 ± 1.9 | 95.1 ± 1.7 | |
| 8 | 91.6 | 94.9 | 2.6 | 4.2 | 98.6 ± 2.7 | 92.6 ± 2.4 | 103.6 ± 4.7 | |
| Norneosildenafil | 0.06 | 105.2 | 90.8 | 5.9 | 5.4 | 89.8 ± 6.4 | 105.8 ± 5.7 | 86.7 ± 9.4 |
| 0.5 | 100.9 | 95.3 | 1.5 | 3.1 | 95.7 ± 1.7 | 100.7 ± 1.5 | 94.4 ± 4.0 | |
| 8 | 98.5 | 95.2 | 1.9 | 1.3 | 97.9 ± 1.2 | 96.9 ± 1.9 | 96.7 ± 2.6 | |
| Testosterone propionate | 0.2 | 97.1 | 95.2 | 5.9 | 5.1 | 99.8 ± 9.8 | 95.4 ± 7.5 | 104.6 ± 5.5 |
| 2.5 | 103 | 96.8 | 1.7 | 3.1 | 99.6 ± 5.2 | 98.1 ± 3.7 | 96.5 ± 4.8 | |
| 8 | 103.4 | 96 | 1.8 | 3.3 | 101.5 ± 3.6 | 105.7 ± 2.8 | 97.2 ± 1.9 | |
Fig. 4Extracted ion chromatograms of the representative positive sample.
Fig. 5The library research results of compound-I and III.
Fig. 6(a) MS2 fragment ions of compound-II and (b) the proposed fragmentation pathways forits main fragment ions.